Comparative pharmacodynamic and pharmacokinetic study of MIDD0301 and its (S) enantiomer
Sign Up to like & getrecommendations! Published in 2022 at "Drug Development Research"
DOI: 10.1002/ddr.21926
Abstract: MIDD0301 is being developed as an oral drug to relax airway smooth muscle (ASM) and reduce lung inflammation in asthma. We report a comparative study of MIDD0301 and its S isomer (MIDD0301S), and found that… read more here.
Keywords: pharmacokinetic study; comparative pharmacodynamic; pharmacodynamic pharmacokinetic; midd0301 ... See more keywords
IN SILICO STUDIES ON DIACYL DERIVATIVES OF PHLOROGLUCINOL TO ENHANCE PHARMACODYNAMIC AND PHARMACOKINETIC PROFILES OF 2,4,6-TRIHYDROXY-3-GERANYL-ACETOPHENONE
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Applied Pharmaceutics"
DOI: 10.22159/ijap.2021v13i2.40784
Abstract: Objective: The purpose of this study was to evaluate the LOX inhibitory activity, and predict the drug likeness properties of designed diacyl derivatives of phloroglucinol, using in silico method. Methods: The designed derivatives were subjected… read more here.
Keywords: diacyl derivatives; pharmacodynamic pharmacokinetic; derivatives phloroglucinol; study ... See more keywords
Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics15020549
Abstract: Acid-reducing agents are commonly used for the prevention of aspirin-induced gastrointestinal complications such as peptic ulcers. As a novel potassium-competitive acid blocker, fexuprazan is expected to prevent aspirin-induced gastrointestinal complications. This randomized, open-label study aimed… read more here.
Keywords: fexuprazan; aspirin induced; pharmacodynamic pharmacokinetic; novel potassium ... See more keywords